Skip to main content
SpringerLink
Log in

Does the addition of vinorelbine to hormone therapy prolong survival of men with hormone-refractory prostate cancer?

  • Practice Point
  • Published:

From Nature Clinical Practice Urology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Eisenberger MA et al. (1985) A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3: 827–841

    Article  CAS  Google Scholar 

  2. Yagoda A and Petrylak DP (1993) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71 (Suppl 3): 1098–1109

    Article  CAS  Google Scholar 

  3. Tannock IF et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756–1764

    Article  CAS  Google Scholar 

  4. Eisenberger MA et al. (2004) A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). J Clin Oncol 22 (Suppl): abstract 4

    Article  Google Scholar 

  5. Pummer K et al. (1997) Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32 (Suppl 3): 81–85

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Suzanne Farley, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Associate Professor in the Department of Urology, Medical University Graz, Austria

    Karl Pummer

Authors
  1. Karl Pummer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karl Pummer.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pummer, K. Does the addition of vinorelbine to hormone therapy prolong survival of men with hormone-refractory prostate cancer?. Nat Rev Urol 2, 80–81 (2005). https://doi.org/10.1038/ncpuro0089

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0089

  • Springer Nature Limited

Search

Navigation